Skip to content

Vasoactive intestinal peptide (VIP, aviptadil) studies: 420 papers with results

Page 2 of 9

  1. Penile erections induced by vasoactive intestinal peptide and sodium nitroprusside.

    Wang R · Urological research · 1993

    Animal study (in vivo) · cat · 4 results

  2. Effect of vasoactive intestinal peptide on myocardial contractility and coronary blood flow in the dog: comparison with isoproterenol and forskolin.

    Anderson FL · Journal of cardiovascular pharmacology · 1988

    Animal study (in vivo) · dog · 7 results

  3. Effect of vasoactive intestinal peptide on pacemaker location and heart rate in the dog atrium.

    Pintér A · Canadian journal of physiology and pharmacology · 1998

    Animal study (in vivo) · dog · 9 results

  4. Vasoactive intestinal polypeptide facilitates atrioventricular nodal conduction and shortens atrial and ventricular refractory periods in conscious and anesthetized dogs.

    Rigel DF · Circulation research · 1990

    Animal study (in vivo) · dog · 8 results

  5. Local cerebral blood flow following the intrastriatal administration of vasoactive intestinal peptide or peptide histidine isoleucine in the rat.

    Tuor UI · Regulatory peptides · 1990

    Animal study (in vivo) · rat · 2 results

  6. Vasoactive intestinal polypeptide (VIP) inhibits prostaglandin-F2 alpha-induced activity of the rabbit myometrium.

    Ottesen B · Prostaglandins · 1980

    Animal study (in vivo) · rabbit · 1 result

  7. Release of oxytocin and vasopressin by intracerebroventricular vasoactive intestinal polypeptide.

    Bardrum B · Endocrinology · 1988

    Animal study (in vivo) · rat · 12 results

  8. Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration.

    Gao X · Journal of controlled release : official journal of the Controlled Release Society · 2007

    Animal study (in vivo) · mouse and rat · 4 results

  9. Vasotocin and vasoactive intestinal polypeptide modulate aggression in a territorial songbird, the violet-eared waxbill (Estrildidae: Uraeginthus granatina).

    Goodson JL · General and comparative endocrinology · 1998

    Animal study (in vivo) · violet-eared waxbill · 1 result

  10. Evidence that vasoactive intestinal polypeptide is a physiological prolactin-releasing factor in the bantam hen.

    Macnamee MC · General and comparative endocrinology · 1986

    Animal study (in vivo) · bantam hen · 8 results

  11. Inhibitory effects of pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) on food intake in the goldfish, Carassius auratus.

    Matsuda K · Peptides · 2005

    Animal study (in vivo) · goldfish (carassius auratus) · 2 results

  12. Intracerebroventricular injection of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibits feeding in chicks.

    Tachibana T · Neuroscience letters · 2003

    Animal study (in vivo) · chick · 3 results

  13. Intestinal secretion induced by vasoactive intestinal polypeptide. A comparison with cholera toxin in the canine jejunum in vivo.

    Krejs GJ · The Journal of clinical investigation · 1978

    Animal study (in vivo) · dog · 8 results

  14. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice.

    Voice JK · Journal of immunology (Baltimore, Md. : 1950) · 2003

    Animal study (in vivo) · mouse · 8 results

  15. Assessment of the effects of vasoactive intestinal peptide (VIP) on blood flow through and salivation of the dog salivary gland in comparison with those of secretin, glucagon and acetylcholine.

    Shimizu T · British journal of pharmacology · 1979

    Animal study (in vivo) · dog · 5 results

  16. Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain.

    Dufes C · International journal of pharmaceutics · 2004

    Animal study (in vivo) · mouse · 3 results

  17. Comparative studies of the angiogenic activity of vasoactive intestinal peptide, endothelins-1 and -3 and angiotensin II in a rat sponge model.

    Hu DE · British journal of pharmacology · 1996

    Animal study (in vivo) · rat · 4 results

  18. Effects of vasoactive intestinal peptide on plasma prolactin in passerines.

    Maney DL · General and comparative endocrinology · 1999

    Animal study (in vivo) · western scrub-jay, white-crowned sparrow and dark-eyed junco · 4 results

  19. Neuroprotection of the developing brain by systemic administration of vasoactive intestinal peptide derivatives.

    Gressens P · The Journal of pharmacology and experimental therapeutics · 1999

    Animal study (in vivo) · mouse · 1 result

  20. Vasoactive intestinal peptide stimulates ACTH and corticosterone release after injection into the PVN.

    Alexander LD · Regulatory peptides · 1994

    Animal study (in vivo) · rat · 2 results

  21. Effect of vasoactive intestinal polypeptide (VIP) upon myometrial blood flow in non-pregnant rabbit.

    Ottesen B · Acta physiologica Scandinavica · 1981

    Animal study (in vivo) · rabbit · 3 results

  22. Comparison of secretin and vasoactive intestinal peptide on pancreatic secretion in dogs.

    Konturek SJ · Gastroenterology · 1975

    Animal study (in vivo) · dog · 5 results

  23. Vascular effects of helodermin, helospectin I and helospectin II: a comparison with vasoactive intestinal peptide (VIP).

    Grundemar L · British journal of pharmacology · 1990

    Animal study (in vivo) · rat · 6 results

  24. Protective effect of vasoactive intestinal peptide on testicular torsion-detorsion injury: association with heparin-containing mast cells.

    Can C · Urology · 2004

    Animal study (in vivo) · rat · 3 results

  25. Regional haemodynamic responses to pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide in conscious rats.

    Gardiner SM · British journal of pharmacology · 1994

    Animal study (in vivo) · rat · 11 results

  26. Exocrine secretion of epidermal growth factor by the rat prostate: effect of adrenergic agents, cholinergic agents, and vasoactive intestinal peptide.

    Jacobs SC · The Prostate · 1988

    Animal study (in vivo) · rat · 3 results

  27. Neural vasodilator control in the rectum of the cat and its possible mediation by vasoactive intestinal polypeptide.

    Andersson PO · The Journal of physiology · 1983

    Animal study (in vivo) · cat · 3 results

  28. The effects of vasoactive intestinal peptide on monocrotaline induced pulmonary hypertensive rabbits following cardiopulmonary bypass: a comparative study with isoproteronol and nitroglycerine.

    Gunaydin S · Cardiovascular surgery (London, England) · 2002

    Animal study (in vivo) · rabbit · 8 results

  29. Effects of vasoactive intestinal peptide on prolactin secretion in three species of passerine birds.

    Vleck CM · General and comparative endocrinology · 1999

    Animal study (in vivo) · blue jay, mexican jay and zebra finch · 8 results

  30. The effect of vasoactive intestinal peptide (VIP) on mast cell invasion/degranulation in testicular interstitium of immobilized + cold stressed and beta-endorphin-treated rats.

    Tunçel N · Peptides · 1996

    Animal study (in vivo) · rat · 4 results

  31. Vasoactive intestinal peptide inhibits the steroid-induced LH surge in the ovariectomized rat.

    Weick RF · The Journal of endocrinology · 1992

    Animal study (in vivo) · rat · 3 results

  32. Comparison of the vasodilatory effects of vasoactive intestinal polypeptide (VIP) and peptide-HI (PHI) in the rabbit and the cat.

    Nilsson SF · Acta physiologica Scandinavica · 1987

    Animal study (in vivo) · cat and rabbit · 9 results

  33. Protective effects of vasoactive intestinal peptide (VIP) in ischemic retinal degeneration.

    Szabadfi K · Journal of molecular neuroscience : MN · 2012

    Animal study (in vivo) · rat · 3 results

  34. Vasoactive intestinal peptide enhances striatal plasticity and prevents dopaminergic cell loss in Parkinsonian rats.

    Korkmaz O · Journal of molecular neuroscience : MN · 2012

    Animal study (in vivo) · rat · 4 results

  35. Effect of vasoactive intestinal peptide on vagally mediated tracheal pouch relaxation.

    Venugopalan CS · Respiration physiology · 1984

    Animal study (in vivo) · guinea pig · 5 results

  36. Central administration of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide differentially regulates energy metabolism in chicks.

    Tachibana T · Comparative biochemistry and physiology. Part A, Molecular & integrative physiology · 2007

    Animal study (in vivo) · domestic chick · 4 results

  37. Effect of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on pancreatic, hepatic and duodenal mucosal bicarbonate secretion in the pig.

    Glad H · Digestion · 2003

    Animal study (in vivo) · pig · 5 results

  38. Effects of substance P and vasoactive intestinal polypeptide on contractile activity and epithelial transport in the ferret jejunum.

    Greenwood B · Gastroenterology · 1990

    Animal study (in vivo) · ferret · 5 results

  39. Vasoactive intestinal peptide suppresses migrating myoelectric complex of rat small intestine independent of nitric oxide.

    Ljung T · Acta physiologica Scandinavica · 1999

    Animal study (in vivo) · rat · 2 results

  40. A comparison of the effects of vasoactive intestinal polypeptide on secretion from the submaxillary gland of the sheep and pig.

    Reid AM · Regulatory peptides · 1988

    Animal study (in vivo) · pig and sheep · 8 results

  41. Comparative effects of synthetic and natural vasoactive intestinal peptide on pancreatic and biliary secretion and on glucose and insulin blood levels in the dog.

    Makhlouf GM · Scandinavian journal of gastroenterology · 1978

    Animal study (in vivo) · dog · 9 results

  42. Vasoactive intestinal polypeptide increases whole pancreatic blood flow but does not affect islet blood flow in the rat.

    Jansson L · Acta diabetologica · 1994

    Animal study (in vivo) · rat · 5 results

  43. Role of vasoactive intestinal polypeptide in burn-induced oedema formation.

    Lindblom L · Burns : journal of the International Society for Burn Injuries · 2000

    Animal study (in vivo) · rat · 7 results

  44. Cyclic nucleotides and vasoactive intestinal peptide production in a rabbit model of Escherichia coli septicemia.

    Broner CW · The American journal of the medical sciences · 1995

    Animal study (in vivo) · rabbit · 4 results

  45. Vasodilator action of guinea pig vasoactive intestinal polypeptide (VIP): comparison with common mammalian VIP.

    Naruse S · Regulatory peptides · 1992

    Animal study (in vivo) · dog and guinea pig · 7 results

  46. Importance of vasoactive intestinal polypeptide in the regulation of burn perfusion.

    Lindblom L · Burns : journal of the International Society for Burn Injuries · 2000

    Animal study (in vivo) · rat · 9 results

  47. Role of vasoactive intestinal peptide (VIP) in pathogenesis of ethanol-induced gastric mucosal damage in rats.

    Karmeli F · Digestive diseases and sciences · 1993

    Animal study (in vivo) · rat · 6 results

  48. Vasoactive intestinal peptide in the amygdala inhibits tail flick reflexes in rats.

    Shin MS · Brain research · 2005

    Animal study (in vivo) · rat · 1 result

  49. Expression of vasoactive intestinal polypeptide receptor mRNA and secretory regulation by vasoactive intestinal polypeptide in rat submandibular and sublingual salivary glands.

    Takai N · Archives of oral biology · 1997

    Animal study (in vivo) · rat · 6 results

  50. Effect of synthetic chicken and porcine vasoactive intestinal peptide on pancreatic blood flow in dogs.

    Inoue K · Neuropeptides · 1986

    Animal study (in vivo) · dog · 6 results

How PepBank reports evidence